

## CURRENT REPORT

Reporting date: **26.10.2023**

Name of the issuing entity: **Antibiotice SA**

Registered office: **lași, str. Valea Lupului nr.1, cod poștal 707410,**

**<http://www.antibiotice.ro>**

E-mail: **relatiicuinvestitorii@antibiotice.ro**

Phone/fax number: **+40232 209000 / 0372 065 633**

Sole Registration Code with the Trade Register Office: **RO1973096**

Order number in the Trade Register Office: **J22/285/1991**

Subscribed and paid share capital: **67.133.804 lei**

Regulated market on which the issued securities are traded: **Bucharest Stock Exchange**

Number of shares: **671.338.040**

The main characteristics of the securities issued by the trading company: **registered shares, nominal value: 0.10 lei**

### Important event to be reported:

**Antibiotice lași has multiplied its export 9 times in the last twenty years.**

**We build the future together with our partners!**

These days, for the 20<sup>th</sup> consecutive year, Antibiotice lași is present at the most important exhibition event in the world pharmaceutical industry, CPhI Worldwide, which this year takes place in Barcelona, Spain.

This large-scale event represents the main engine for the development of international businesses, which, over time, have been multiplied several times, our company forecasting to reach a value of 215 million lei at the end of this year, representing 36% of the turnover.

*"In the last 20 years, we have consolidated partnerships with large companies from all over the world and we are here, at this international exhibition, to convey to them that, in a divided world, in a world where we seem to no longer find each other, we are capable of building a future together with our partners", declared Ioan Nani, Antibiotice CEO.*

The Antibiotice team attending CPhI Worldwide, made up of specialists in research and development, portfolio management, import, export, business development, marketing and sales has over 150 meetings with business partners from all over the world, in order to identify new opportunities for expanding our businesses in the global market by exploiting our company's research and production infrastructure.

By participating in such international events, Antibiotice sends a message of stability and continuity to its partners, with whom it aims **to double its foreign business affairs until 2030**, in line with the strategic development plan “The Future Together”.

At the end of 2022, Antibiotice inaugurated the most modern plant in Europe for topical medicines, 20 million euro investment, thus consolidating its position as a national leader in the manufacture of pharmaceutical topical products. With a capacity higher by 50% than the old one and meeting the highest production and quality standards, this investment offers our company a greater openness to international markets which are characterized by a high degree of competitiveness and innovation.

In May 2023, Antibiotice obtained also the approval for non-reimbursable funds amounting to over 85 million lei for a manufacturing capacity for sterile products, solutions and topicals.

The new production capacities along with 100 new products attracted in the portfolio up to the horizon of 2030, are an integral part of the company's strategic development plan “The Future Together” which aims at doubling the turnover, profit and increasing the market shares both domestically and internationally.

Therefore, our 20-year continuous presence at CPHI Worldwide represents a premise for expanding and consolidating our business in foreign markets alongside our partners, Antibiotice being the most important Romanian manufacturer of generic medicines with international recognition, exporting in 70 countries worldwide.

General Manager,  
Ec. Ioan NANI